No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
When we read this September 25, 2015 Medscape article, “EMA Recommends Approval of Idarucizumab (Praxbind), a Dabigatran-Specific Antidote”, we recalled this alarming fact: At the present time there is...
View ArticleXarelto / Savaysa / Pradaxa / Eliquis: Effect Of Platelet Inhibitors
Some newer oral anticoagulants have been associated with bleeding-related adverse reactions including gastrointestinal and intracranial bleeds. And that problem is the primary complaint that the...
View ArticleEliquis Might Be Safer Than Xarelto, But Neither Has Approved Antidote
In a November 9, 2015 news report, “Antithrombotics Have Varied Risk of Causing Major Bleeds”, there is a summary of one presentation the American Heart Association 2015 Scientific Sessions:...
View ArticleEliquis, Savaysa, And Xarelto Worry Doctors Because No Antidote, Still
A few recent articles address the fact there is no way to quickly restore normal clotting for patients in need of emergency surgery or to stop a major bleeding episode while on Eliquis, Savaysa, and...
View ArticlePossible Blood Level Testing For Eliquis / Xarelto / Pradaxa / Savaysa
As background, Xarelto (rivaroxaban) belongs to a class of medicines known as the direct oral anticoagulants (DOAC), which also includes Pradaxa (dabigatran), Eliquis (apixaban), and Savaysa...
View ArticleDoctors Are Concerned About Lack Of Savaysa Antidote To Stop Bleeding
I think it is interesting how this recent Healio – HemOnc Today news reports, “Edoxaban safe, effective for extended prevention of recurrent VTE”, ends by focusing on the continuing lack of any...
View ArticleAntidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval
The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary...
View ArticleSeptember 2016 Savaysa Label Change Points Out There Is Still No Antidote
Savaysa (edoxaban) is a factor Xa inhibitor which was approved by the FDA in 2015. Savaysa has the following so-called “indications” or approved uses: To reduce the risk of stroke and systemic embolism...
View ArticleNo Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis...
View ArticlePradaxa And Xarelto May Double The Risk Of Heart Attacks Some Patients
In March 2017 the British Journal of Clinical Pharmacology published this article, “Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct...
View Article
